AiTan (rivoceranib)

P=N/A, N=150, Recruiting, Fudan University | Not yet recruiting --> Recruiting

P=N/A, N=941, Completed, Zhongda Hospital | Recruiting --> Completed | N=220 --> 941 | Trial completion date: Sep 2023 --> Sep 2025

P=N/A, N=1244, Completed, Zhongda Hospital | Recruiting --> Completed | N=474 --> 1244

P2, N=78, Recruiting, The First Affiliated Hospital of Zhengzhou University | N=36 --> 78

P3, N=572, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting

Disease stabilization was achieved using cadonilimab, apatinib, and ifosfamide/etoposide...An individualized, multimodal treatment approach may extend survival. scRNA-seq provides valuable insights into the molecular landscape of MTT and hold promise for guiding precision therapy in the future.

P=N/A, N=5, Terminated, Peking Union Medical College Hospital | N=70 --> 5 | Trial completion date: Oct 2028 --> Mar 2026 | Not yet recruiting --> Terminated | Trial primary completion date: Oct 2027 --> Mar 2026; Results failed to achieve the anticipated effect.

In summary, we present a targeted nanoplatform that enhances the antitumor efficacy of Apa at lower dosages by leveraging ferroptosis induction. This strategy holds promise for improving the clinical outcomes in patients with GC.

Treatment involved a multimodal strategy combining transarterial chemoembolization (TACE), fractionated radiotherapy, and combination immunotherapy with camrelizumab plus apatinib. This case highlights the rare entity of direct renal invasion from HCC and provides practical insights into its diagnosis and comprehensive management. It illustrates the clinical feasibility and potential benefit of a combined locoregional and systemic strategy in advanced HCC with such uncommon extrahepatic renal involvement, underscoring the importance of individualized treatment in these complex presentations.

P2, N=48, Recruiting, Asan Medical Center | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Aug 2026 --> Aug 2027

P2, N=39, Recruiting, Peking Union Medical College | Trial primary completion date: Jul 2026 --> Jul 2028

An increase in the frequency of CD8 + T-cells and a decreased frequency of tissue-resident memory 1 (Trm-1) and regulatory T (Treg) cells are associated with a favorable response to neoadjuvant therapy. Spatiotemporal multiomics analysis highlighted tissue-resident macrophages as potential predictive biomarkers and warrants further verification.